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Monitoring viral infection after allogeneic stem
cell transplantation–single center experience
A. Tanase ∗, A. Colita, C. Orban
Fundeni Clinical Institute, Bucharest, Romania
Background: Viral infections after stem cell transplant are less
frequently reported compared to bacterial or fungal infections, but
usually are more severe and associated with high mortality.
Methods & Materials: This study analyzes the incidence and
outcome of viral infections and correlation with immunosuppress-
ive therapy in 67 patients (13 children and 54 adults) receiving
allogeneic stem cell transplantation and evaluated in BoneMarrow
Transplant center, Fundeni Clinical Institute, Bucharest. Standard
prophylactic treatment was Acyclovir 1000mg per day during
transplant procedure and 180 days after allogeneic HSCT. We
assessed–patient and donor CMV, EBV status before allogeneic
HSCT. All patients were monitorized with RT-PCR for CMV, EBV,
ADV, VZV, HSV-1, HHV-6, HHV-8 and with Nested PCR for JCV, BKV
ﬁrst year after allotransplant.
Results: The viral diagnosis showed 13 pediatric cases (7
reactivation of CMV, 3 CMV disease, 1 EBV reactivation, 1 HHV-
6 encephalitis, 2 polyomavirus cystistis) and 15 adult cases (11
reactivation of CMV, 2 with EBV reactivation and 2 with BK virus).
5 of 18 patients developed primary CMV infection. 14 from 28
patients had a positive PCR viral load in ﬁrst 180 days after allo-
geneic HSCT. 20 patients from 28 associated clinical signs of acute
or chronic GVHD.
Conclusion: The most severe clinical aspects have been asso-
ciated with severe immunosupresion for GVHD. Early detection of
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Background:Up today there are12 serologically different types
of avian paramyxovirus. Full genome sequences of almost all of
them were published in GenBank. In this study molecular-genetics
examinations of new unknown APMV isolate were done.
Methods & Materials: APMV isolate was obtained in 2011
from cloacal swabs of goose (Anser albifrons) and marked as
APMV/white-fronted goose/Ukraine/2011. Serological examina-
tion of new isolate was provided using monoclonal antibodies
in haemagglutination-inhibition tests against APMV1-9.Total RNA
from the isolate was obtained using TRI Reagent. RT-PCR, cloning
into TOPO and plasmid puriﬁcation, sequencing and phylogenic
analysis were done as described previously (Diel DG et al., 2011).
Results: As the results obtained isolate showed cross reactions
with APMV7. Using random DNA library it was found 3 regions,
which could identify by BLAST. The ﬁrst region with the length
of 367bp had 70% nucleotide sequence identity to the APMV 12
isolate Wigeon/Italy/3920 1/2005 at genome position 2419-2784.
Next region (344bp) had 66% identity to the same APMV 12 isolate
at position 4760-5103. The last region (365bp) showed 71% iden-
tity to Newcastle disease virus strain M4 at position 12569-12928.
This high divergence from the currently known APMV allows us to
make the assumption that this isolate might be a new serotype of
APMV, but it needs to obtain full genome-sequencing and detailed
study of the biological properties of the virus.
Conclusion: According to the obtained results we have con-
ﬁrmed circulation of new unknown APMV in wild birds on the
territory of Ukraine. Obtained isolate showed moderate similarity
to APMV 12 and APMV 1.
http://dx.doi.org/10.1016/j.ijid.2014.03.1344
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Hepatitis B vaccine knowledge and uptake
among medical students in Cameroon
N.J.R. Nansseu1,∗, N.J.J. Noubiap2
1 Mother and Child Centre, Yaounde, Cameroon
2 Edea Regional Hospital, Edea, Cameroon
Background: Hepatitis B virus (HBV) is the most contagious
blood borne pathogen. The risk of occupational exposure to HBV
among health care workers is a major concern, especially among
medical trainees. In this study, we describe the knowledge of risk
factors for HBV infection, history of accidental exposure to blood,
awareness of HBV vaccine and the vaccination status among med-
ical students in Cameroon.
Methods & Materials: In April 2012, a cross-sectional survey
was carried out using a pretested self-administered questionnaire
among 111 medical students
Results: Sixty-two students (55.9%) had had at least one acci-
dental exposure to blood since the beginning of their medical
training, with a median of 2 (IQR, 1-3) exposures. There was a good
knowledge of the risk factors for HBV infection and awareness of
HBV vaccine among participants. However, only 20 (18%) partici-
pants had completed the three doses of primary HBV vaccination.
Furthermore, only 2 of the 20 (10%) adequately vaccinated par-
ticipants had a post-vaccination test to conﬁrm a good immune
response and thus an effective protection against HBV infection.
The main reason for not being vaccinated was lack of money to
pay for the vaccine (45.6%). Forty seven (42.3%) participants had
been sensitized by their training institutions about the importance
